iTeos Therapeutics Statistics
Share Statistics
iTeos Therapeutics has 36.53M shares outstanding. The number of shares has increased by 2.07% in one year.
| Shares Outstanding | 36.53M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.1% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 30.81M |
| Failed to Deliver (FTD) Shares | 72 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.12M, so 8.54% of the outstanding shares have been sold short.
| Short Interest | 3.12M |
| Short % of Shares Out | 8.54% |
| Short % of Float | 10.12% |
| Short Ratio (days to cover) | 4.75 |
Valuation Ratios
The PE ratio is -3.48 and the forward PE ratio is -1.57.
| PE Ratio | -3.48 |
| Forward PE | -1.57 |
| PS Ratio | 31.09 |
| Forward PS | 37.9 |
| PB Ratio | 0.68 |
| P/FCF Ratio | -3.67 |
| PEG Ratio | n/a |
Enterprise Valuation
iTeos Therapeutics Inc. has an Enterprise Value (EV) of 146.49M.
| EV / Earnings | -1.3 |
| EV / Sales | 11.63 |
| EV / EBITDA | -0.97 |
| EV / EBIT | -0.97 |
| EV / FCF | -1.37 |
Financial Position
The company has a current ratio of 13.76, with a Debt / Equity ratio of 0.
| Current Ratio | 13.76 |
| Quick Ratio | 13.76 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.22 |
| Cash Flow / Debt | -82.94 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.2% and return on capital (ROIC) is -26.86%.
| Return on Equity (ROE) | -0.2% |
| Return on Assets (ROA) | -0.17% |
| Return on Capital (ROIC) | -26.86% |
| Revenue Per Employee | 80.22K |
| Profits Per Employee | -717.46K |
| Employee Count | 157 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 3.61M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -29.31% in the last 52 weeks. The beta is 1.39, so iTeos Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.39 |
| 52-Week Price Change | -29.31% |
| 50-Day Moving Average | 8.81 |
| 200-Day Moving Average | 12.9 |
| Relative Strength Index (RSI) | 38.58 |
| Average Volume (20 Days) | 681.84K |
Income Statement
In the last 12 months, iTeos Therapeutics had revenue of $12.60M and earned -$112.64M in profits. Earnings per share was $-3.15.
| Revenue | 12.60M |
| Gross Profit | 11.70M |
| Operating Income | -151.10M |
| Net Income | -112.64M |
| EBITDA | -151.10M |
| EBIT | -151.10M |
| Earnings Per Share (EPS) | -3.15 |
Balance Sheet
The company has $251.18M in cash and $6.06M in debt, giving a net cash position of $245.12M.
| Cash & Cash Equivalents | 251.18M |
| Total Debt | 6.06M |
| Net Cash | 245.12M |
| Retained Earnings | 124.63M |
| Total Assets | 723.08M |
| Working Capital | 508.06M |
Cash Flow
In the last 12 months, operating cash flow was -$103.76M and capital expenditures -$2.97M, giving a free cash flow of -$106.72M.
| Operating Cash Flow | -103.76M |
| Capital Expenditures | -2.97M |
| Free Cash Flow | -106.72M |
| FCF Per Share | -2.98 |
Margins
Gross margin is 92.87%, with operating and profit margins of -1.20K% and -894.34%.
| Gross Margin | 92.87% |
| Operating Margin | -1.20K% |
| Pretax Margin | -865.66% |
| Profit Margin | -894.34% |
| EBITDA Margin | -1.20K% |
| EBIT Margin | -1.20K% |
| FCF Margin | -847.34% |
Dividends & Yields
ITOS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -41.07% |
| FCF Yield | -38.09% |
Analyst Forecast
The average price target for ITOS is $24, which is 212.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 212.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 2.21 |
| Piotroski F-Score | 1 |